ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)–Harbour BioMed (HBM) and Erasmus MC, University Medical Center Rotterdam
announced today that they have signed a 10-year Memorandum of
Understanding (MOU) to enable a broad range of joint basic,
translational and clinical research activities aimed at developing next
generation biotherapeutics for the treatment of cancer and immunological
diseases. The MoU was signed during the official, 40^th
anniversary celebration ceremony of the Shanghai-Rotterdam Sister City
Relationship.

Under the MoU, HBM expects to establish laboratory space in Rotterdam to
facilitate scientific collaborations with Erasmus MC investigators
across multiple departments. The company and Erasmus MC have established
an umbrella CDA to expedite collaboration discussions. In addition, HBM
plans to run its Phase I and II clinical trials at Erasmus MC, which
will also serve as the base for larger clinical trials across Europe of
its growing therapeutic portfolio.

“This MoU will advance the company’s vision of growing its footprint in
Europe and provide a foundation for strengthening our scientific and
business collaborations with Erasmus MC,” said Dr. Jingsong Wang,
Founder, Chairman and CEO of HBM. “Working under the broader umbrella of
the MoU will allow a broad range of collaborations between our two
organizations to discover breakthrough therapies that can be rapidly
developed and tested in clinical trials.”

Professor Ernest J. Kuipers, CEO of Erasmus MC, stated, “This expanded
partnership, which builds on the strong, longstanding relationship we
have established with HBM, provides a framework for discovering and
advancing innovative drugs into clinical trials to address unmet needs
of patients with cancer and immunological diseases. Such collaborations
between industry and academic institutions like Erasmus MC provide an
important avenue for scientists and clinicians to advance basic and
clinical science.”

The Mayor of Rotterdam, Mr. Ahmed Aboutaleb, also commented in support
of the MoU, “The collaboration between Harbour BioMed and Erasmus MC
offers diverse opportunities for the city of Rotterdam as well as for
Shanghai: employability, knowledge and a chance of realizing better
treatments of certain types of cancers and immune-mediated diseases.”

Harbour BioMed has collaborated with Erasmus MC since its inception in
2016, when the company acquired Harbour Antibodies, an Erasmus MC
spin-out commercializing two transgenic mouse platforms for producing
fully human antibodies. Since that time, HBM and Erasmus MC have worked
closely apply these powerful platform technologies for the discovery of
novel therapeutics.

About Erasmus MC
Erasmus MC is the largest University
Medical Center in the Netherlands. Our primary goal is a healthy
population. Nearly 14,000 employees devote themselves every day to
providing outstanding care, facilitating world-class education and
conducting pioneering research. These professionals are instrumental in
developing expertise on health and illness. They link the latest
scientific insights to practical treatments and prevention measures to
provide maximum benefit to patients and to enable healthy people to stay
healthy longer. Being visibly better and leading the way in the areas of
complex, innovative and acute care by collaborating with others: these
are key ambitions at Erasmus MC.

About Harbour BioMed
Harbour BioMed is a global, clinical
stage biopharmaceutical company developing innovative therapeutics in
the fields of immuno-oncology and inflammatory diseases. The company is
building its proprietary pipeline through internal R&D programs,
collaborations with co-discovery and co-development partners and select
acquisitions. The company’s discovery and development programs are
centered around its two patented transgenic mouse platforms for
generating fully human monoclonal antibodies. Harbour BioMed also
licenses the platforms to companies and academic institutions. The
company has operations in Cambridge, Massachusetts; Rotterdam, The
Netherlands; and Shanghai, China. For more information, visit www.harbourbiomed.com.

Contacts

Atul Deshpande, PhD
Chief Strategy Officer and Head of U.S.
Operations
Harbour BioMed
Tel. +1 617-682-3679
Email: atul.deshpande@harbourbiomed.com